ERBB2 and metastatic neoplasm: We next retrospectively examined the impact of HSP90 expression on progression-free survival and overall survival (PFS and OS) of 72 patients with HER2+ breast cancer undergoing first-line treatment for metastatic disease with either trastuzumab plus chemotherapy or combined trastuzumab/pertuzumab plus chemotherapy.